Posts Tagged low dead space syringes

New Blunt Cannula Technology | QD Syringe Systems®

Saturday, April 29th, 2017 | Permalink

New Blunt Cannula Technology

Ready, set, go! QD Syringe Systems, LLC. introduces a revolutionary product to enter the market soon – Quick Draw Syringe™, the world’s first fully functional low dead space basic syringe. The Quick Draw Syringe or QD Syringe is touted as the next generation of basic functional disposable syringes which will completely eliminate the need for the outdated nonfunctional basic luer lock syringe. It’s an easier, safer alternative for medical professionals to use. Our QD Syringe Systems team is currently working on a QD Neutral Displacement Needleless Connector which will enable the quick accessibility of the QD Syringe’s tip but will also allow for basic current luer lock syringes universal ISO 80369 syringe comparability.


“With so many changes in technology, we decided that there was a great need for not just a new disposable syringe but one that vastly improved the function, safety and efficiency of it. And with the rising costs of healthcare, there was also a need for a basic syringe that was cost-effective. The QD Syringe is faster, more efficacious and simplifies the process of withdrawing medication from a rubber stopper vial and injecting it into a patient or within seconds, immediately delivers medication into a patient’s luer access split septum,” says Christopher Green, CEO and co-founder of QD Syringe Systems. QD Syringe is simple – open the package and it’s fully functional.


Basic syringes nationwide haven’t had a design change in decades and while they work, they aren’t as effective as they could be. The basic Luer Lock syringe is essentially dependent on two needles with hubs, one to draw the medication into its chamber and the second to deliver the medication to its intended patient. Current basic syringes waste costly medications, up to 42 microliters in its separate draw needle and up to 42 microliters left in the vial and often leaving up to 84 microliters of residual medication volume in the syringe tip and hub after patient delivery. This means up to 168 microliters of expensive medication is wasted. With the GlyFlo Technology™, the QD syringe has a uniquely patented and integrated cone-shaped tip with channels which allows the QD Syringe to extract all of the medication necessary from rubber stopper vials and to deliver that costly medicine to patients effectively. “The QD Syringe leaves as little as 18 microliters of residual volume from draw to patient delivery, which drastically cuts the waste of costly medications by 89.5%. This is a massive money-saving benefit to the healthcare industry and consumers,” says Christopher Green.


Because of the high dead space in current basic syringes, blood can linger on the tip and inside of its hub which has been shown to encapsulate dangerous living pathogens for many weeks. However, the QD Syringe has a blunt tip with bilateral drying channels (like an inside out needle), causing blood not to pool which makes it much safer for medical experts and reduces the spread of infectious diseases. In addition, the QD Syringe can access both pre-slit, non-pre-slit injection receptacles and has its own ultra sharp steel needle with hub which mates over the cone-shaped GlyFlo tip for immediate patient access.


Video: QD Syringe Drawing Medication From a Vial
Video: QD Syringe Delivering IV Injection through the BD Q-Syte™ Luer Access Split Septum
Video: QD Syringe Drawing Medication From a Vial & Injecting a Patient


© 2017 QD Syringes Systems ~ The QD Syringe is a patented product registered with the U.S. Patent Office.

For More information Contact:

Christopher Green at 954-655-4145


Syringes are a Surprising Source of Wasted Medication

Monday, November 14th, 2016 | Permalink


Syringes are a surprising source of wasted medication

Better syringe design can save thousands of dollars per year

(Chapel Hill, N.C., June 6) – When medicine is injected, a little bit of it stays behind in the syringe. It’s not much, but depending on syringe design and the cost of the drug, this waste — or dead space — can add up to as much as $2,300 per year for a patient, according to a new study from researchers at the University of North Carolina at Chapel Hill and RTI International.

Syringe dead space is the leftover fluid that remains inside the syringe after the plunger is fully depressed. In syringes with a lot of dead space, the leftover amount averages to three percent of the volume of the medication dose. In syringes with a low-dead-space design, the volume of leftover medication averages 10 times less at 0.3 percent.

“It is a difference of fractions of a milliliter, but when some of these medications cost more than $20,000 a month, it adds up,” said Christine Oramasionwu, lead author of the study and an assistant professor in the nation’s No. 1 ranked UNC Eshelman School of Pharmacy. “Low-dead-space design, like those with an integrated needle or a cone-shaped plunger, should be adopted as the industry standard for all syringes in order to reduce preventable and expensive medication waste.”

UNC-Chapel Hill and RTI researchers, whose work is reported in the June 6 issue of JAMA Internal Medicine, identified 17 medications administered using high-dead-space syringes and seven using low-dead-space syringes. The total volume of the injection ranged from one-fourth to five milliliters for high-dead-space medications and 0.08 to one milliliters for low-dead-space medications. The median cost for a month’s supply of medication packaged in high-dead-space syringes was $4,443 and $3,412 for low-dead-space syringes.

The median value of the wasted medicine per dose was $5 for high-dead-space medications and about fifty cents for low-dead-space medications. Over one year, the cost of the waste for high-dead-space medications ranged from $558 to $2,329 (a median value of $1,638) compared to $68 to $205 (a median value of $125) for low-dead-space medications.

The researchers reported the median, or middle value, of most monetary ranges because of the high variability of cost among the relatively small number of medications included in the study. The high and low price for a 30-day supply of the 17 high-dead-space medications was $50 and $20,552. The high and low price for a 30-day supply of the seven low-dead-space medications was $716 and $29,728.


About the University of North Carolina at Chapel Hill

The University of North Carolina at Chapel Hill, the nation’s first public university, is a global higher education leader known for innovative teaching, research and public service. A member of the prestigious Association of American Universities, Carolina regularly ranks as the best value for academic quality in U.S. public higher education. Now in its third century, the University offers 77 bachelor’s, 113 master’s, 68 doctorate and seven professional degree programs through 14 schools and the College of Arts and Sciences. Every day, faculty – including two Nobel laureates – staff and students shape their teaching, research and public service to meet North Carolina’s most pressing needs in every region and all 100 counties. Carolina’s more than 308,000 alumni live in all 50 states and 150 countries. More than 167,000 live in North Carolina.

 UNC Communications and Public Affairs contact: Thania Benios, (919) 962-8596,

UNC Eshelman School of Pharmacy contact: David Etchison, (919) 966-7744,






QD Syringe | The First Fully Functional Syringe

Saturday, October 1st, 2016 | Permalink

BPA Free GlyFlo Tip – The QD Syringe is a BPA Free Medical Syringe.



The QD Syringe has been touted as the next generation of safer and more effective syringes to enter the market – the Quick Draw Syringe™. The Quick Draw Syringe or the QD Syringe is a revolutionary product that will be the world’s first fully functional basic low dead space syringe with detachable and low residual volume QD hubs with needles.

Created by Christopher Green, CEO and co-founder of QD Syringe Systems Inc., this patented eco-friendly product is unique in the fact that it is fully functional out of its package, it is safer and easier for medical professionals to use and a low dead space syringe that tremendously reduces medication waste and residual volume. The QD Syringe was also designed for pre-filled syringe use. Headquartered in St. Petersburg, Florida, QD Syringe Systems, Inc. CEO says the design of basic syringe hasn’t been updated in decades. Until now. Introducing the QD Syringe. The QD Syringe is a BPA free medical syringe device.


What are Low Dead Space Syringes?

Thursday, December 26th, 2013 | Permalink

qd-syringe-low-dead-space-syringeDead space in needles and syringes wastes billions of dollars, contributes to vaccine shortages and leads to inaccurate dosing. Dead space in needles and syringes also contributes to HIV and hepatitis C virus transmission among people who inject drugs. There are a number of alternative needle and syringe designs that reduce or eliminate dead space. Several major syringe manufacturers have patented these designs. However, there is no real financial incentive for them to phase out the production of standard needles and syringes and replace them with low dead space alternatives. Our aim is to bring about a change by increasing demand for low dead space needles and syringes and reducing demand for standard needles and syringes.

Visit :::

Low “Dead Space” Syringes Could Save Your Life

Thursday, February 2nd, 2012 | Permalink

Another guest article from Jamie Bridge this week. This time he’s writing about some of the work of researcher Dr. William Zule, looking into how the type of syringe someone uses may have an inpact on their risk of getting the HIV virus. I have had this article a few weeks but it was embargoed until the AIDS2010 conference started as its finding are being presented there.

How syringe type effects HIV risk

New research being presented this week at the International AIDS Conference in Vienna has made a strong link between different types of syringe and levels of HIV transmission through sharing.

Every needle-syringe, when the plunger is fully depressed, retains some fluid or blood in what is termed “dead-space”. Some syringe designs have more of this “dead space” than others – especially those with detachable needles. Depending on the design, some syringes can retain 84 microlitres of fluid. This is a very, very small amount – but other syringe designs can retain as little as 2 microlitres.

So the hypothesis is simple: if you share a syringe with higher “dead-space”, then there will be more blood retained in the syringe and you will be more likely to become infected with blood-borne viruses. If you share a low “dead space” syringe, you are still putting yourself at risk – but perhaps less so, as there is less blood retained when the plunger is fully down.

Previous modelling work by Dr William Zule and colleagues in the USA tried to quantify what this could mean in the real world. The results suggested that injection-related HIV epidemics might not occur when most (95% or more) of injectors use syringes with low “dead space”. If everyone uses higher “dead space” syringes, then HIV prevalence can reach 50% among injectors in just seventeen years. When just one in ten sharing events involve high “dead space” syringes, then HIV prevalence can stabilize.

The findings, albeit theoretical, have clear implications for harm reduction programs. However, in Vienna, the research has been taken to the next level. Data from multi-year HIV prevalence studies were gathered from 35 cities in 20 countries, and local needle exchange workers were contacted to find out what types of syringe were mainly used.

In cities where high “dead space” syringes were mainly used, the average HIV prevalence among injectors was 32.6% (and went up as high as 73%). In cities where low “dead space” syringes were mainly used, the average was just 1.4%. When the data were analyzed, the type of syringe was the only factor closely associated with this pattern in HIV.

More research needs to be done on this topic, and expect to hear a lot more about this in the future – this is an important finding which could have a big impact on harm reduction and the advice given to injectors. Of course, the biggest message is that ALL needle-syringe sharing is a risk. However, if we could reduce HIV transmission simply by providing one kind of syringe over another, then this is something that must be rolled out as soon as possible. Do you know what kind of syringe your local exchange supplies?

A big thank you to Dr William Zule for sharing this research.

Jamie Bridge, MSc, currently works in the Technical Publications and Learning Team of the Global Fund to Fight AIDS, Tuberculosis and Malaria. Before moving to Geneva in 2010, he worked for the International Harm Reduction Association in London, coordinating the international harm reduction conferences. Before that, he also worked in a needle and syringe program in Bedford. Jamie also works voluntarily with UKHRA and the NNEF .